Tag Archives: WHO

Antibiotics Discovery: Time for a ‘Manhattan Project’

by Susan Crowley The innovative pharmaceutical industry is under attack from critics around the world for failing to develop new antibiotics to treat emerging infections. The charge has been furthered by statements from World Health Organization (WHO) director Margaret Chan. In 2012, she warned that bacteria were starting to become so resistant to common antibiotics […]
Posted in Corporate Responsibility, Global, Guest Blog, healthcare, IP, leadership, Manufacturing, Market Access, R&D, Strategy | Also tagged , , , , , , | 4 Comments

Assessing the Value of Retrospective Studies: Real-World Data, Real-World Applications

by Sarah Ray The value of retrospective studies cannot be overstated. Retrospective studies affect many healthcare sectors, including the pharmaceutical industry and general public health. Applying these studies provides clear advantages at different points of the product life-cycle. During drug development, these studies may help clinical teams propose adaptations or even a companion diagnostic tests […]
Posted in Gene therapy, Global, Guest Blog, healthcare, R&D, Strategy | Also tagged , , , , , , , , , , | Leave a comment

UN Pact Scuttles Anti-Vaccine Provision

A new international agreement to reduce mercury contamination of air and water was recently adopted by 140 countries, without a proposal that threatened to limit access to vaccines in much of the world. The credit goes to public health authorities and medical experts who challenged a provision blocking production of vaccines with the preservative thimerosal, […]
Posted in Emerging Markets, FDA, Global, healthcare, Legal, Market Access, Patient Communication, Safety | Also tagged , , , , , | 2 Comments

Measuring Responsibility in Big Pharma

Measuring Responsibility in Big Pharma If you can’t measure it, the saying goes, it doesn’t count.  But what if you’re measuring the wrong things? The Access to Medicines Index (www.accesstomedicineindex.org) is an attempt to measure and compare the corporate social responsibility of both innovator (20) and generics (7) companies based on a number of different […]
Posted in Corporate Responsibility, Guest Blog, healthcare | Also tagged , , , , | Leave a comment

Will WHO Member States Pony Up for Neglected Diseases?

Recognizing that traditional market forces – namely incentives related to intellectual property and a steady demand for products – have failed in developing countries, the World Health Organization (WHO) asked a member state-nominated group to come up with ways to fund R&D and pay for the treatment of neglected diseases in the world’s poorest nations. […]
Posted in Emerging Markets, Global, IP, leadership, Legal, Manufacturing, Market Access, pricing, R&D | Also tagged , , , , , , , , , | Leave a comment
  • Categories

  • Meta